Recognizing the deviation from the NIHB formulary could potentially cost more money than expected and have other impacts, but I will commit to continue to look at off-label drugs and the positive impacts of off-label drugs on a one-off basis.
Tom Beaulieu on Question 144-17(3): Off-Label Use Of Prescription Drugs
In the Legislative Assembly on June 13th, 2012. See this statement in context.
Question 144-17(3): Off-Label Use Of Prescription Drugs
Oral Questions
June 12th, 2012
See context to find out what was said next.